Вопросы актуализации российских клинических рекомендаций по диагностике и лечению анкилозирующего спондилита и псориатического артрита

1. Эрдес Ш., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Гайдукова И.З., Годзенко А.А., и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-660. doi: 10.14412/1995-4484-2015-657-660

2. Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T. Health-related quality of life in patients with ankylosing spondylitis: A comprehensive review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):857-872. doi: 10.1586/14737167.2014.957679

3. Zochling J, Braun J. Mortality in ankylosing spondylitis. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S80-S84.

4. Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Curr Opin Rheumatol. 2010;22(4):375-380. doi: 10.1097/BOR.0b013e32833ac5cc

5. Анкилозирующий спондилит: клинические рекомендации. 2018.URL: http://cr.rosminzdrav.ru/#!/schema/175 (Дата доступа: 14.02.2021).

6. Лила А.М., Древаль Р.О., Шипицын В.В. Оценка организации медицинской помощи и лекарственного обеспечения при ревматических заболеваниях и социально-экономического бремени этих болезней в Российской Федерации. Современная ревматология. 2018;12(3):112-119. doi: 10.14412/1996-7012-2018-3-112-119

7. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: An overview. Ann Rheum Dis. 2002;61(Suppl III):iii8-iii18.

8. Коротаева Т.В., Корсакова Ю.Л., Логинова Е.Ю., Губарь Е.Е., Чамурлиева М.Н. Псориатический артрит. Клинические рекомендации по диагностике и лечению. Современная ревматология. 2018;12(2):22-35. doi: 10.14412/1996-7012-2018-2-22-35

9. Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: Patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3:91-102. doi: 10.1007/s40744-016-0029-z

10. Coates LC, Orbai AM, Azevedo VF, Cappelleri JC, Steinberg K, Lippe R, et al. Impact of psoriatic arthritis from the patient’s perspective in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire: An online global survey. Arthritis Rheumatol. 2018;70(Suppl 10). URL: https://acrabstracts.org/abstract/impact-of-psoriatic-arthritis-from-the-patients-perspective-in-the-context-of-the-psoriatic-arthritis-impact-of-diseasepsaid-questionnaire-an-online-global-survey/ (Accessed: 15th February 2021).

11. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-568. doi: 10.1016/j.rdc.2015.07.001

12. Haddad A, Zisman D. Comorbidities in patients with psoriatic arthritis. Rambam Maimonides Med J. 2017;8(1):e0004. doi: 10.5041/RMMJ.10279

13. Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40(8):1349-1356. doi: 10.3899/jrheum.121500.

14. Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: Descriptive analyses from an administrative claims database. J Manag Care Spec Pharm. 2018;24(7):623-631. doi: 10.18553/jmcp.2018.24.7.623

15. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62(7):965-969. doi: 10.1002/acr.20155

16. Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, Effectiveness and drug survival of TNFinhibitors in the treatment of psoriatic arthritis: A prospective cohort study. Semin Arthritis Rheum. 2017;46(6):732-739. doi: 10.1016/j.semarthrit.2016.09.005

17. Lubrano E, Perrotta FM, Scriffignano S, Coates LC, Helliwell P. Sustained very low disease activity and remission in psoriatic arthritis patients. Rheumatol Ther. 2019;6:521-528. doi: 10.1007/s40744-019-00171-w

18. Инструкция по медицинскому применению препарата РАНВЭК. URL: https://grls.rosminzdrav.ru/GRLS.aspx (Дата доступа: 22.02.2021).

19. van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):21082117. doi: 10.1016/S0140-6736(19)32534-6

20. Deodhar A, van der Heijde D, Sieper J, van den Bosch F, Maksymowych W, Kim TH, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis: 1-year results from a randomized, double-blind, placebo-controlled study with open-label extension. Arthritis Rheumatol. 2020;72 (Suppl 10). URL: https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-patients-with-active-ankylosing-spondylitis-1-yearresults-from-a-randomized-double-blind-placebo-controlledstudy-with-open-label-extension/ (Accessed: 14th February 2021).

21. Deodhar A, Baraliakos X, McInnes I, de Vlam K, Bessette L, Maniccia A, et al. Effect of upadacitinib on reducing pain in patients with active ankylosing spondylitis and inadequate response to nonsteroidal anti-inflammatory drugs. Arthritis Rheumatol. 2020;72 (Suppl 10). URL: https://acrabstracts.org/abstract/effect-of-upadacitinib-on-reducing-pain-in-patients-with-active-ankylosing-spondylitis-and-inadequate-response-to-nonsteroidal-anti-inflammatory-drugs/ (Accessed: 14th February 2021).

22. Cohen S, van Vollenhoven R, Winthrop K, Zerbini CA, Tanaka Y, Bessette L, et al. Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT Phase 3 clinical program. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/safety-profile-of-upadacitinib-in-rheumatoid-arthritis-integrated-analysis-from-the-select-phase-3-clinical-program/ (Accessed: 14th February 2021).

23. Burmester G, Winthrop K, Nash P, Goupille P, Azevedo VF, Salvarani C, et al. Safety profile of upadacitinib in psoriatic arthritis: Integrated analysis from two phase 3 trials. Arthritis Rheumatol. 2020;72(Suppl 10). URL: https://acrabstracts.org/abstract/safety-profile-of-upadacitinib-in-psoriatic-arthritis-integrated-analysis-from-two-phase-3-trials/ (Accessed: 12th April 2021).

24. EMA SmPC RINVOQ. URL: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq#product-informationsection (Accessed: 9th February 2021).

25. McInnes I, Anderson J, Magrey M, Merola J, Liu Y, Kishimoto M, et al. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease-modifying anti-rheumatic drugs: A double-blind, randomized controlled phase 3 trial. Arthritis Rheumatol. 2020;72(Suppl 10). URL: https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-versus-placebo-and-adalimumab-in-patients-with-active-psoriatic-arthritis-and-inadequate-response-to-non-biologic-disease-modifying-anti-rheumatic-drugs-a-double-b/ (Accessed: 14th February 2021).